Life Sciences in Norway 2025

We are excited to announce the publication of Life Sciences in Norway 2025, which provides an in-depth exploration of the life sciences sector in Norway. The publication offers valuable insights into the legal landscape governing pharmaceuticals, biotechnology, health services, and medical devices, and covers a wide array of topics, including the regulatory framework, key supervisory bodies, pre-marketing activities, pricing and reimbursements, post-marketing activities, and intellectual property rights.
BAHR’s life sciences practice is renowned for representing leading pharmaceutical originators in complex patent disputes and has extensive expertise in pharmaceutical regulations. We are adept at navigating regulatory issues, including pricing, reimbursement, market access, competition law and public procurement, and provide counsel on commercial agreements, intellectual property, licensing agreements, clinical trials, M&A, and technology transfers.
We invite you to explore this publication to gain a deeper understanding of the legal framework governing the life sciences sector in Norway.